We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byCaroline Küchler
Modified over 4 years ago
Patterns of Treatment and Outcomes for Definitive Therapy of Early Stage Non-Small Cell Lung Cancer Nirav S. Kapadia, MD, MS, Luca F. Valle, MD, Julie A. George, MS, Reshma Jagsi, MD, DPhil, Thomas A. D’Amico, MD, Elisabeth U. Dexter, MD, Fawn D. Vigneau, JD, MPH, Feng Ming Kong, MD, PhD The Annals of Thoracic Surgery Volume 104, Issue 6, Pages (December 2017) DOI: /j.athoracsur Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions
Fig 1 Percent distribution of non-small cell lung cancer (NSCLC) staging as defined by the American Joint Committee on Cancer (AJCC) between the years 2000 and Histogram divided into early stage (I and II) disease in blue and late stage (III and IV) disease in red for ease of comparison. The Annals of Thoracic Surgery , DOI: ( /j.athoracsur ) Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions
Fig 2 Distribution of definitive therapy for stage I non-small cell lung cancer (NSCLC) between 2000 and The proportion of patients undergoing surgery during this time span are represented in red. Patients treated with combined surgery and radiation therapy (RT) are represented in purple. Patients treated with RT only are represented in blue. Patients receiving neither RT nor surgery are represented in green. Patients with unknown treatment details are represented in black. The Annals of Thoracic Surgery , DOI: ( /j.athoracsur ) Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions
Fig 3 Annual proportions of (A) all treatments and (B) types of surgery used to treat Stage I non-small cell lung cancer (NSCLC) between 2000 and For A, types of treatments include surgery (blue), combined surgery and radiation therapy (RT) (yellow), radiation therapy (green), or no treatment (red). Types of surgery in B include pneumonectomy (green), lobectomy (red), or sublobar resection (blue). The Annals of Thoracic Surgery , DOI: ( /j.athoracsur ) Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions
Fig 4 Survival outcomes for stage I non-small cell lung cancer (NSCLC) by definitive treatment type, 2000 to Kaplan-Meier survival curves, in months, for the years 2000 (red), 2002 (orange), 2004 (yellow), 2006 (green), 2008 (blue), and 2010 (purple) in (A) all patients, (B) patients receiving radiation therapy only, and (C) patients receiving surgery only. The Annals of Thoracic Surgery , DOI: ( /j.athoracsur ) Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions
Elizabeth A. David, MD, David T
Outcomes of Major Lung Resection After Induction Therapy for Non-Small Cell Lung Cancer in Elderly Patients Chi-Fu Jeffrey Yang, MD, Nicholas R. Mayne,
Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes Meng S. Shao, MD, Andrew T. Wong, MD,
Survival After Surgical Resection for Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease Anders Bugge, MD, May Brit Lund, MD, PhD, Cathrine.
Thomas J. Birdas, MD, Richard P. M
Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F
Surgical Management of Advanced Non-Small Cell Lung Cancer Is Decreasing But Is Associated With Improved Survival Elizabeth A. David, MD, Robert J. Canter,
Comparison of Thoracoscopic Segmentectomy and Thoracoscopic Lobectomy for Small-Sized Stage IA Lung Cancer Chenxi Zhong, MD, Wentao Fang, MD, Teng Mao,
Chun Chieh Lin, PhD, MBA, Matthew P
Joshua E. Rosen, BASc, Hari B
Ravi Rajaram, MD, MSc, Jennifer L
Sarcomatoid Carcinoma of the Lung: A Predictor of Poor Prognosis
Elliot Wakeam, MD, MPH, Meredith Giuliani, MBBS, MEd, Natasha B
Paul J. Scheel, BS, Traves D. Crabtree, MD, Jennifer M
Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD
Benjamin E. Lee, MD, Mark Shapiro, MD, John R. Rutledge, MAS, Robert J
Osteopontin Combined With CD44v6, a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer Undergoing Curative Resection Bing-sheng Sun, MD, PhD, Yue.
A Model to Predict the Use of Surgical Resection for Advanced-Stage Non-Small Cell Lung Cancer Patients Elizabeth A. David, MD, Stina W. Andersen, PhD,
Video-Assisted Thoracic Surgery Lobectomy: Experience With 1,100 Cases
Castigliano M. Bhamidipati, DO, MS, George J
© 2023 SlidePlayer.com Inc. All rights reserved.